-
Published02/10/2025
-
Deadline03/11/2025
-
Opening of tenders03/11/2025
-
Today15/11/2025
Utilities
- indicates CPV codes deduced from the text of the procedure
- indicates text translated automatically in your browsing language
Supply of a repaid form of Bevacizumab 100 mg/4 ml and 400 mg/ 16 ml for intravenous use Text automatically translated in your browsing language Automatically translated
Subject-matter of these supplies: Supply of a repaid form of Bevacizumab 100 mg/4 ml and 400 mg/ 16 ml for intravenous use. It is expected that the tenderer will make available annually approximately 21 % of the estimated annual consumption as a medical sample at the request of the doctors to administer the product outside of reimbursable indications (cf. in accordance with the Royal Decree of 11 January 1993 laying down the conditions under which medicinal products for human use may be handed over in the form of samples). Text automatically translated in your browsing language Automatically translated
https://www.publicprocurement.be
https://www.publicprocurement.be
33600000 - Pharmaceutical products
33140000 - Medical consumables CVP code deduced from the text of the procedure AI-generated
33100000 - Medical equipments CVP code deduced from the text of the procedure AI-generated
Type: cost
Description: Netto kost ziekenhuis
Weight (percentage, exact): 50
Criterion:
Type: quality
Description: Gebruiksgemak en veiligheid verpakking
Weight (percentage, exact): 30
Criterion:
Type: quality
Description: Leveringsgarantie en leveringstermijn
Weight (percentage, exact): 20
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.